Corcept Therapeutics

Yahoo Finance • 24 hours ago

Plant Biotechnology Company Evaluation Report 2025 | Bayer, Syngenta, and BASF Lead with Advanced Crop Protection, Seeds, and Sustainable Farming Solutions

Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Plant Biotechnology - Company Evaluation Report, 2025" report has been added to ResearchAndMarkets.com's offering. The Plant Biotechnology Companies Quadrant is a comprehensive industry... Full story

Yahoo Finance • 3 days ago

Corcept therapeutics officer sells $2.5M in shares

William Guyer, Chief Development Officer at Corcept Therapeutics Inc (NASDAQ:CORT), sold 35,007 shares of common stock on August 8, 2025, for $71.77, totaling approximately $2.5 million. The sale was executed under a prearranged 10b5-1 t... Full story

Yahoo Finance • 10 days ago

Corcept therapeutics officer Lyon sells $393k in shares

Joseph Douglas Lyon, Chief Accounting & Technology Officer at Corcept Therapeutics (NASDAQ:CORT), sold 5,823 shares of common stock on August 1, 2025, for approximately $393,127. The shares were sold at a weighted average price of $67.51... Full story

Yahoo Finance • 19 days ago

Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 11 Best Long Term Low Risk Stocks to Invest in. The company completes a key drug study and has submitted a new drug application to the U.S. FDA.Corcept Therapeutics Advances Pi... Full story

Yahoo Finance • 23 days ago

Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 13 Best Low Risk High Growth Stocks to Buy. Analysts are reiterating their Buy rating for the stock amid advancements in ovarian cancer treatment.Corcept Advances Cancer Drug a... Full story

Yahoo Finance • last month

Corcept Submits NDA For Relacorilant To Treat Platinum-Resistant Ovarian Cancer

(RTTNews) - Corcept Therapeutics Incorporated (CORT), a commercial-stage biopharma company focused on cortisol modulation, has submitted a New Drug Application - NDA to the U.S. FDA for relacorilant in combination with nab-paclitaxel for t... Full story

Yahoo Finance • last month

Corcept seeks FDA approval for ovarian cancer treatment

[Cortisol molecular structure. 3D illustration] HT Ganzo/iStock via Getty Images * Corcept Therapeutics (NASDAQ:CORT [https://seekingalpha.com/symbol/CORT]) has submitted a marketing application to the U.S. FDA for its cortisol modulato... Full story

Yahoo Finance • last month

Piper Sandler reiterates Overweight rating on Corcept Therapeutics stock

Investing.com - Piper Sandler has reiterated an Overweight rating and $131.00 price target on Corcept Therapeutics (NASDAQ:CORT) following insights from an expert call on the company’s relacorilant treatment for ovarian cancer. The compa... Full story

Yahoo Finance • last month

Corcept therapeutics officer Guyer sells $7350 in shares

William Guyer, Chief Development Officer at Corcept Therapeutics Inc (NASDAQ:CORT), sold 100 shares of common stock on July 1, 2025, at a price of $73.505, for a total value of $7350. The transaction comes as Corcept, with a market capit... Full story

Yahoo Finance • 2 months ago

Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances

Introduction & Market Context Corcept Therapeutics (NASDAQ:CORT) presented its May 2025 corporate overview highlighting the company’s financial trajectory and expanding pipeline in cortisol modulation therapies. The presentation comes as... Full story

Yahoo Finance • 2 months ago

Corcept's mid-stage ALS study fails to meet main goal

[Microscopic of Neural network Brain cells] fatido/E+ via Getty Images Corcept Therapeutics (NASDAQ:CORT [https://seekingalpha.com/symbol/CORT]) said on Thursday that the mid-stage study of its cortisol modulator, dazucorilant, in patient... Full story

Yahoo Finance • 3 months ago

Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other best performing healthcare stocks t... Full story

Yahoo Finance • 3 months ago

Corcept Therapeutics price target lowered to $135 from $150 at Truist

Truist analyst Joon Lee lowered the firm’s price target on Corcept Therapeutics (CORT) to $135 from $150 and keeps a Buy rating on the shares. The company’s Q1 Korlym revenue of $157.2M was softer than expected due to bandwidth issues with... Full story

Yahoo Finance • 3 months ago

Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Jim Simons’ RenTech’s 10 Small-Cap Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against Bil... Full story

Yahoo Finance • 4 months ago

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other Guru stocks to invest... Full story

Yahoo Finance • 4 months ago

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

REDWOOD CITY, Calif., April 23, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metaboli... Full story

Yahoo Finance • 4 months ago

Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday?

We recently published a list of 10 Firms Kick Off Trading Week Stronger. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other firms that kicked off the trading week stro... Full story

Yahoo Finance • 6 months ago

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

REDWOOD CITY, Calif., February 12, 2025--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2024 financial results and provide a corporate update on February 26, 20... Full story

Yahoo Finance • 10 months ago

3 US Growth Stocks With Insider Ownership And 20% Revenue Growth

As the U.S. stock market experiences a rally, with major indices like the S&P 500 and Nasdaq climbing due to gains in large-cap technology stocks, investors are keenly observing economic indicators such as interest rate adjustments and oil... Full story

Yahoo Finance • 11 months ago

Does Corcept Therapeutics (CORT) Have a Long Runway for Growth?

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Value Strategy” second quarter 2024 investor letter. A copy of the letter can be downloaded here. Despite strong performance from healthcare hol... Full story